# 68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer

> **NCT03389451** · PHASE2,PHASE3 · COMPLETED · sponsor: **Michael Graham PhD, MD** · enrollment: 30 (actual)

## Conditions studied

- Prostate Cancer
- Prostatic Neoplasm
- Prostatic Neoplasms, Castration-Resistant
- Prostatic Cancer Recurrent
- Prostatic Cancer Metastatic

## Interventions

- **DRUG:** Ga-68 PSMA-HBED-CC PET

## Key facts

- **NCT ID:** NCT03389451
- **Lead sponsor:** Michael Graham PhD, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-16
- **Primary completion:** 2019-07-23
- **Final completion:** 2019-07-23
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-07-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03389451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03389451, "68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03389451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*